Author:
Wang Ligang,Wang Ying,Xie Qiqi,Xu Songcheng,Yang Chen,Liu Fei,Liu Yang,Wang Fuwei,Chen Weinan,Li Jianchun,Sun Litao
Reference37 articles.
1. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature;Adnane;Methods Enzymol.,2006
2. Liposomes in the targeted gene therapy of cancer: a critical review;Akkewar;Curr. Drug Deliv.,2023
3. PI3K/AKT/mTOR dysregulation and reprogramming metabolic pathways in renal cancer: crosstalk with the VHL/HIF axis;Badoiu;Int. J. Mol. Sci.,2023
4. Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment;Bahadoram;Giornale Ital. Nefrol.,2022
5. Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma;Braun;Nat. Rev. Clin. Oncol.,2021